For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development-Related Party | 1,982 | 5,549* | 5,817 | 2,932 |
| Research and development-Nonrelated Party | 45,518 | 33,092* | 27,158 | 21,866 |
| General and administrative | 12,742 | 8,127* | 7,701 | 7,220 |
| Total operating expenses | 60,242 | 46,767 | 40,676 | 32,018 |
| Loss from operations | -60,242 | -46,767* | -40,676 | -32,018 |
| Interest income | 4,083 | 4,269 | 4,386 | 4,682 |
| Total other income | 4,083 | 4,269* | 4,386 | 4,682 |
| Net loss before income taxes | -56,159 | -42,498* | -36,290 | -27,336 |
| Income tax expense | 52 | 79* | 40 | 52 |
| Net loss | -56,211 | -42,577* | -36,330 | -27,388 |
| Unrealized loss on marketable securities, net of tax | -486 | 651 | -136 | - |
| Total other comprehensive loss | -486 | 651* | -136 | - |
| Total comprehensive loss | -56,697 | -41,926 | -36,466 | - |
| Basic EPS | -0.93 | -0 | -0.67 | -0.5 |
| Diluted EPS | -0.93 | -0 | -0.67 | -0.5 |
| Basic Average Shares | 60,717,041 | 163,921,584,906 | 54,563,864 | 54,539,230 |
| Diluted Average Shares | 60,717,041 | 163,921,584,906 | 54,563,864 | 54,539,230 |
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)